Prosecution Insights
Last updated: November 04, 2026

Ipx LLC

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Ipx LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner, PALENIK, JEFFREY T, and is located within 1 distinct art unit. The busiest examiner for the portfolio is PALENIK, JEFFREY T, who is responsible for the 1 pending office action currently active.

With 1 pending office action and 1 distinct examiner, the prosecution focus is entirely on this matter. The matching counts of 1 examiner, 1 art unit, and 1 action mean that the company's current USPTO activity is centralized. Practitioners only need to address the specific requirements of the assigned examiner within that art unit to move the case forward. This scope of pending activity reduces the complexity of managing multiple deadlines or different examiner requirements across the Biotechnology & Pharmaceuticals sector. The art unit assignment provides a technical framework for the pending case.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PALENIK, JEFFREY T 1 53.5% +27.1%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18776567 PERSONAL CARE DISSOLVABLE SHEET, COMPOSITIONS, METHODS OF MAKING AND USING THE SAME PALENIK, JEFFREY T —

Top Art Units

Art UnitApps
1615 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18776567 PERSONAL CARE DISSOLVABLE SHEET, COMPOSITIONS, METHODS OF MAKING AND USING THE SAME PALENIK, JEFFREY T 1615 §103 Non-Final OA — Pending Jul 18, 2024

Managing Ipx LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Ipx LLC have?

Ipx LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Ipx LLC applications?

Jeffrey T Palenik has the most, with 1 of Ipx LLC's pending office actions.

What technology area are Ipx LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month